DiversimAb™ Mouse Technology

Enhanced Epitopic Diversity for Your Most Challenging Targets

The limitation of most in vivo discovery platforms is the diversity of the host animal's immune response. The DiversimAb™ mouse platform is designed to deliver maximum antibody diversity. Our proprietary mice can generate rare murine antibodies against epitopes and proteins with high homology to mouse orthologs. By combining Twist’s industry-leading hybridoma and deep B cell screening platforms with DiversimAb, targeting even the most challenging targets is possible.

mice diversimab

 

Our platform is commonly used for generating various types of antibodies

It also produces antibodies targeting cell surface receptors, anti-mouse surrogate antibodies, and essential anti-idiotype reagents.

Therapeutic and reagent antibodies 

Antibodies with customized cross-reactivity 

Highly specific antibodies

Potent antibodies 

Comparing Antibody Titers from DiversimAb™ and Balb/c Mice

We’ve analyzed antibody responses for DiversimAb mice, DiversimAb mice pre-immunization, and Balb/c mice across antigen homologies of 75%, 87%, 96%, and 100%. At each level of homology, the cohort of DiversimAb mice (green) had the most potent antibody response, followed by the Balb/c mice (purple) with a moderate response and the pre-immune DiversimAb group (gold) with minimal response. Across all dilutions, from 1:300 to 1:72900, DiversimAb mice consistently demonstrate a superior antibody response, even when immunizing with an antigen of 100% homology.

immune

 

Enhanced Epitopic Diversity for Your Most Challenging Targets

The limitation of most in vivo discovery platforms is the diversity of the host animal's immune response. The DiversimAb™ mouse platform is designed to deliver maximum antibody diversity. Our proprietary mice can generate rare murine antibodies against epitopes and proteins with high homology to mouse orthologs. By combining Twist’s industry-leading hybridoma and deep B cell screening platforms with DiversimAb, targeting even the most challenging targets is possible.

mice diversimab

 

Our platform is commonly used for generating various types of antibodies

It also produces antibodies targeting cell surface receptors, anti-mouse surrogate antibodies, and essential anti-idiotype reagents.

Therapeutic and reagent antibodies 

Antibodies with customized cross-reactivity 

Highly specific antibodies

Potent antibodies 

Comparing Antibody Titers from DiversimAb™ and Balb/c Mice

We’ve analyzed antibody responses for DiversimAb mice, DiversimAb mice pre-immunization, and Balb/c mice across antigen homologies of 75%, 87%, 96%, and 100%. At each level of homology, the cohort of DiversimAb mice (green) had the most potent antibody response, followed by the Balb/c mice (purple) with a moderate response and the pre-immune DiversimAb group (gold) with minimal response. Across all dilutions, from 1:300 to 1:72900, DiversimAb mice consistently demonstrate a superior antibody response, even when immunizing with an antigen of 100% homology.

immune

 

AVANTAGES

A Different Discovery Experience with DiversimAb™

Découvrez-en plus grâce à une panoplie complète d’outils et de services pour l’ingénierie et l’optimisation des anticorps. Notre plateforme TAO met à votre disposition l’expertise scientifique de nos ingénieurs anticorps et des technologies innovantes pour accélérer la recherche et le développement de biomédicaments.

Diversité accrue des anticorps

DiversimAb™ mice provide an advantage in nearly any custom antibody discovery application due to the increased epitopic diversity of the mAbs generated. As a benefit of enhanced antibody diversities, the DiversimAb™ platform readily enables the discovery of species' cross-reactive antibodies, including human, cyno, and mouse cross-reactive antibodies.

 

Difficult, High-Homology Epitope Targeting

Our auto-immune, hyperimmune model enables the delivery of antibodies against difficult targets, including cell surface receptors and epitopes that do not elicit a robust immune response in natural mice. We've delivered antibodies against 100% Mus musculus proteins using DiversimAb™ mice.

Purpose-Built and Rapid Immunization Strategies for Tough Targets

Twist uses proprietary, customizable immunization protocols optimized for DiversimAb™ for multipass membrane proteins including GPCRs, ion channels, high-homology targets, and poor immunogens. These rapid immunization strategies can elicit robust immune responses in weeks rather than months, delivering leads without sacrificing affinity or quality.

Royalty-Free Use

Twist offers royalty-free, flexible business models, including fee-for-service and partnership structures, to access our DiversimAb™ platform for your most challenging targets and high-profile programs.

A Different Discovery Experience with DiversimAb™

Découvrez-en plus grâce à une panoplie complète d’outils et de services pour l’ingénierie et l’optimisation des anticorps. Notre plateforme TAO met à votre disposition l’expertise scientifique de nos ingénieurs anticorps et des technologies innovantes pour accélérer la recherche et le développement de biomédicaments.

Diversité accrue des anticorps

DiversimAb™ mice provide an advantage in nearly any custom antibody discovery application due to the increased epitopic diversity of the mAbs generated. As a benefit of enhanced antibody diversities, the DiversimAb™ platform readily enables the discovery of species' cross-reactive antibodies, including human, cyno, and mouse cross-reactive antibodies.

 

Difficult, High-Homology Epitope Targeting

Our auto-immune, hyperimmune model enables the delivery of antibodies against difficult targets, including cell surface receptors and epitopes that do not elicit a robust immune response in natural mice. We've delivered antibodies against 100% Mus musculus proteins using DiversimAb™ mice.

Purpose-Built and Rapid Immunization Strategies for Tough Targets

Twist uses proprietary, customizable immunization protocols optimized for DiversimAb™ for multipass membrane proteins including GPCRs, ion channels, high-homology targets, and poor immunogens. These rapid immunization strategies can elicit robust immune responses in weeks rather than months, delivering leads without sacrificing affinity or quality.

Royalty-Free Use

Twist offers royalty-free, flexible business models, including fee-for-service and partnership structures, to access our DiversimAb™ platform for your most challenging targets and high-profile programs.

RESSOURCES TECHNIQUES

Ressources techniques

DiversimAb™ Case Studies

Case studies Biopharma

Download the case study

DiversimAb™  Mouse for Antibody Discovery

Service SheetBiopharma

Download the service sheet

Ressources techniques

DiversimAb™ Case Studies

Case studies Biopharma

Download the case study

DiversimAb™  Mouse for Antibody Discovery

Service SheetBiopharma

Download the service sheet

En savoir plus

La référence Twist pour la recherche d’anticorps

Fiche de produitAnticorps

Téléchargez la fiche produit

Optimisation et ingénierie des anticorps

AfficheBiopharma

Télécharger l’affiche

Twist Express Antibody Production

Fiche de produitBiopharma

Twist Express Antibody Production

Caractérisation et développabilité des anticorps

WebinaireBiopharma

Voir la présentation

Contactez-nous

Nos experts en anticorps se tiennent à votre disposition et aimeraient en savoir plus sur vos besoins en matière de recherche. Les cibles difficiles sont les bienvenues !

Powered by Translations.com GlobalLink Web Software